Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial

Helda Tutunchi ¹ , Fatemeh Naeini ², Maryam Saghafi-Asl ¹, Nazila Farrin ¹, Alireza Monshikarimi ¹ * , Alireza Ostadrahimi ¹ *

Cited by CrossRef: 8

1- Fang X, Davis X, Flack K, Duncan C, Li F, White M, Grilo C, Small D. Dietary adaptation for weight loss maintenance at Yale (DAWLY): Protocol and predictions for a randomized controlled trial. Front Nutr. 2022;9 [Crossref]

2- Wang Y, Fang F, Liu X. Targeting histamine in metabolic syndrome: Insights and therapeutic potential. Life Sciences. 2024;358:123172 [Crossref]

3- Song J, Huang M, Shi X, Li X, Chen X, He Z, Li J, Xu G, Zheng J. T329S Mutation in the FMO3 Gene Alleviates Lipid Metabolic Diseases in Chickens in the Late Laying Period. Animals. 2021;12(1):48 [Crossref]

4- Arefhosseini S, Ebrahimi-Mameghani M, Asghari S, Barzegari A, Roshanravan N. Myo-inositol supplementation in obese patients with non-alcoholic fatty liver disease: Assessment of sirtuin-1 pathway, atherogenic and hematological parameters. Journal of Functional Foods. 2024;116:106197 [Crossref]

5- Kazemi M, Lalooha F, Nooshabadi M, Haghighian H. Decreased dysmenorrhea pain in girls by reducing oxidative stress and inflammatory biomarkers following supplementation with oleoylethanolamide: A randomized controlled trial. J of Obstet and Gynaecol. 2022;48(5):1212 [Crossref]

6- Murillo‐Rodríguez E, Arankowsky‐Sandoval G, Budde H, Imperatori C, Machado S, Yamamoto T, Yadollahpour A, Torterolo P. In vivo brain levels of acetylcholine and 5‐hydroxytryptamine after oleoylethanolamide or palmitoylethanolamide administrations are mediated by PPARα engagement. Eur J of Neuroscience. 2021;54(6):5932 [Crossref]

7- Komolafe O, Buzzetti E, Linden A, Best L, Madden A, Roberts D, Chase T, Fritche D, Freeman S, Cooper N, Sutton A, Milne E, Wright K, Pavlov C, Davidson B, Tsochatzis E, Gurusamy K. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. 2021;2021(7) [Crossref]

8- Tutunchi H, Zolrahim F, Nikbaf-Shandiz M, Naeini F, Ostadrahimi A, Naghshi S, Salek R, Najafipour F. Effects of oleoylethanolamide supplementation on inflammatory biomarkers, oxidative stress and antioxidant parameters of obese patients with NAFLD on a calorie-restricted diet: A randomized controlled trial. Front Pharmacol. 2023;14 [Crossref]

9- Giudetti A, Vergara D, Longo S, Friuli M, Eramo B, Tacconi S, Fidaleo M, Dini L, Romano A, Gaetani S. Oleoylethanolamide Reduces Hepatic Oxidative Stress and Endoplasmic Reticulum Stress in High-Fat Diet-Fed Rats. Antioxidants. 2021;10(8):1289 [Crossref]

10- Xu W, Zhang H, Feng Y, Li S, Xie B. Genetically predicted fatty liver disease and risk of psychiatric disorders: A mendelian randomization study. World J Clin Cases. 2024;12(14):2359 [Crossref]

11- Song J, Shi X, Li X, Liang Q, Zeng L, Li G, Yan Y, Xu G, Zheng J. Associations of the T329S Polymorphism in Flavin-Containing Monooxygenase 3 With Atherosclerosis and Fatty Liver Syndrome in 90-Week-Old Hens. Front Vet Sci. 2022;9 [Crossref]